Exicure (XCUR) announced it has completed patient enrollment in its ongoing Phase 2 clinical trial evaluating the safety and efficacy of GPC-100 in combination with propranolol and G-CSF in multiple myeloma patients undergoing autologous stem cell transplant.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XCUR: